Global Herceptin (Trastuzumab) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Herceptin (Trastuzumab) Market Research Report 2024
Herceptin (Trastuzumab) is a monoclonal antibody against Her2, blocks the growth of cancer cells by attaching itself to Her2, preventing epidermal growth factor from attaching to Her2. Herceptin also stimulates the body's own immune cells to destroy cancer cells. Clinically, it is mainly used for metastatic breast cancer with excessive expression of her-2. Monotherapy may be used for metastatic breast cancer that has received one or more chemotherapy regimens; It can be combined with paclitaxel to treat metastatic breast cancer without chemotherapy.
According to Mr Accuracy reports new survey, global Herceptin (Trastuzumab) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Herceptin (Trastuzumab) market research.
Key manufacturers engaged in the Herceptin (Trastuzumab) industry include Roche Diagnostics, Genentech, Novartis AG, Pfizer, Abnova Corporation, InvivoGen, Celltrion, Biocon Limited and Bio-Techne, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Herceptin (Trastuzumab) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Herceptin (Trastuzumab) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Herceptin (Trastuzumab) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Roche Diagnostics
Genentech
Novartis AG
Pfizer
Abnova Corporation
InvivoGen
Celltrion
Biocon Limited
Bio-Techne
Amgen
Samsung Bioepis
Merck
Mylan
Teva Pharmaceutical
Mundipharma
Mabion
AryoGen Biopharma
Genor Biopharma
Segment by Type
Breast Cancer
Stomach Cancer
Others
Hospital
Medical Center
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Herceptin (Trastuzumab) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Herceptin (Trastuzumab) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Herceptin (Trastuzumab) market research.
Key manufacturers engaged in the Herceptin (Trastuzumab) industry include Roche Diagnostics, Genentech, Novartis AG, Pfizer, Abnova Corporation, InvivoGen, Celltrion, Biocon Limited and Bio-Techne, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Herceptin (Trastuzumab) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Herceptin (Trastuzumab) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Herceptin (Trastuzumab) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche Diagnostics
Genentech
Novartis AG
Pfizer
Abnova Corporation
InvivoGen
Celltrion
Biocon Limited
Bio-Techne
Amgen
Samsung Bioepis
Merck
Mylan
Teva Pharmaceutical
Mundipharma
Mabion
AryoGen Biopharma
Genor Biopharma
Segment by Type
Breast Cancer
Stomach Cancer
Others
Segment by Application
Hospital
Medical Center
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Herceptin (Trastuzumab) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices